An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 and RedirecTT-1 trials. Talquetamab, the bispecific GPRC5D-directed CD3 ...
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with ...
In the present study, also signs were improved including lower esophageal sphincter (LES) pressure (from 10 ± 1.58 and, 10.3 ± 1.68 mmHg in the pretreated patients to 16.5 ± 0.6, and 14.1 ± 0. ...
Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα ...
Preliminary safety and efficacy data from the phase 1 CaDAnCe-101 study demonstrates that BGB-16673 has a tolerable safety profile and shows promising antitumor activity in heavily pretreated ...